Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice
Retatrutide's Current Stage of Clinical Development in the UK Retatrutide is progressing through Phase 3 clinical trials as of April 2026 and cannot be legally prescribed in the UK until it completes trials and receives MHRA authorisation
Protein sources such as low fat Greek Yogurt, eggs, chicken, turkey, fish, lentils, legumes, nuts and seeds are particularly useful here
Scientific Mechanism: The Triple Agonist Revolution The biological efficacy of Retatrutide is derived from its unique molecular architecture as a tri-agonist
No, Botox and dermal fillers are safe to receive while taking GLP-1 medications